Aimmune Therapeutics Inc (NASDAQ:AIMT) – Analysts at Cantor Fitzgerald decreased their FY2017 earnings per share (EPS) estimates for Aimmune Therapeutics in a research report issued on Sunday. Cantor Fitzgerald analyst W. Tanner now anticipates that the biotechnology company will post earnings of ($2.61) per share for the year, down from their previous estimate of ($2.50). Cantor Fitzgerald currently has a “Overweight” rating and a $64.00 target price on the stock. Cantor Fitzgerald also issued estimates for Aimmune Therapeutics’ FY2018 earnings at ($2.49) EPS and FY2019 earnings at ($2.26) EPS.
Several other brokerages also recently weighed in on AIMT. BidaskClub raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Credit Suisse Group set a $45.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Thursday, January 11th. Wedbush reaffirmed an “outperform” rating and set a $70.00 target price on shares of Aimmune Therapeutics in a research note on Friday, December 1st. ValuEngine downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, January 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $57.22.
Shares of Aimmune Therapeutics (AIMT) opened at $33.25 on Wednesday. Aimmune Therapeutics has a 52 week low of $15.97 and a 52 week high of $42.00. The firm has a market cap of $2,035.57, a P/E ratio of -14.15 and a beta of -0.49.
Several large investors have recently made changes to their positions in AIMT. Carillon Tower Advisers Inc. purchased a new stake in shares of Aimmune Therapeutics in the 4th quarter valued at approximately $58,838,000. Alliancebernstein L.P. increased its position in shares of Aimmune Therapeutics by 109.5% in the 4th quarter. Alliancebernstein L.P. now owns 1,400,281 shares of the biotechnology company’s stock valued at $52,959,000 after purchasing an additional 731,927 shares during the last quarter. Citadel Advisors LLC increased its position in shares of Aimmune Therapeutics by 3,092.5% in the 3rd quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock valued at $13,873,000 after purchasing an additional 542,111 shares during the last quarter. Franklin Resources Inc. purchased a new stake in shares of Aimmune Therapeutics in the 4th quarter valued at approximately $18,702,000. Finally, State Street Corp increased its position in shares of Aimmune Therapeutics by 26.6% in the 2nd quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock valued at $22,351,000 after purchasing an additional 228,429 shares during the last quarter. 62.04% of the stock is currently owned by institutional investors.
In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 1,875 shares of the stock in a transaction that occurred on Tuesday, December 26th. The shares were sold at an average price of $39.44, for a total value of $73,950.00. Following the sale, the insider now directly owns 1,875 shares of the company’s stock, valued at approximately $73,950. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Eric Bjerkholt acquired 3,125 shares of the company’s stock in a transaction on Monday, February 26th. The stock was purchased at an average cost of $32.00 per share, for a total transaction of $100,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 58,093 shares of company stock worth $1,858,976 and have sold 133,968 shares worth $5,073,180. 17.59% of the stock is owned by corporate insiders.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.